Skip to main content

Table 1 Circular RNAs implicated in hematological malignancies

From: The functions and clinical significance of circRNAs in hematological malignancies

Disease CircRNA Expression Phenotype Clinical significance Possible target/mechanism Ref.
AML circRNA-DLEU2 Up proliferation ( +), apoptosis (−), tumor formation ( +) / miR-496/PRKACB [125]
circ_100290 Up proliferation ( +), apoptosis (−) / miR-203/Rab10 [23]
circPAN3 Up autophagy ( +), apoptosis (−), ADM-resistance ( +) / miR-153-5p/miR-183-5p/XIAP [14, 43]
circ-ANXA2 Up proliferation ( +), apoptosis (−) high disease risk, poor risk stratification, low CR level, short EFS and OS miR-23a-5p/miR-503-3p [105]
circ_0009910 Up proliferation ( +), apoptosis (−) poor risk, short OS miR-20a-5p [19]
circ_0000370 Up proliferation ( +), apoptosis (−), cell cycle ( +) FLT3-ITD +  miR-1299/S100A7A [26]
circMYBL2 Up proliferation ( +), quizartinib resistance ( +) FLT3-ITD +  PTBP1, FLT3 kinase translational ( +) [25]
circ-VIM Up / distribution of WBC count, FAB subtypes, short OS and LFS / [106]
circ-0004136 Up proliferation ( +) / miR-142 [21]
circ-HIPK2 Down differentiation ( +) ATRA-induced differentiation miR-124-3p [111]
circ_0001947 Down proliferation (−), apoptosis ( +) white blood cell, hemoglobin, diagnosis, prognosis miR-329-5p/CREBRF [22]
circ_0121582 Down proliferation (−) / miR-224/GSK3β, TET1/GSK3β/Wnt/β-catenin [24]
CML circ_0080145 Up proliferation ( +) / sponge miR-29b [20]
circ_0009910 Up proliferation ( +), autophagy ( +), apoptosis (−) imatinib resistance, short OS miR-34a-5p/UKL1 [47]
circBA9.3 Up proliferation ( +), apoptosis (−) TKI-resistance c-ABL1 & BCR-ABL1 level ( +) [45]
circ_100053 Up / clinical stage, BCR/ABL mutant status, short OS, imatinib resistance / [46]
circ_0080145 Up proliferation ( +), glycolysis ( +), apoptosis (−) IM-resistance miR-326/PPFIA1 [15]
ALL circPVT1 Up proliferation ( +), apoptosis (−) / c-Myc & Bcl-2 expression ( +) [27]
circAF4 Up apoptosis (−), leukemogenesis ( +) risk stratification miR-128-3p/MLL-AF4 [96]
CLL circ-CBFB Up progression ( +), apoptosis (−) diagnosis, low survival time, independent predictor of prognosis miR-607/FZD3/Wnt/β-catenin pathway [31]
circ-RPL15 Up proliferation ( +) IGHV mutation status miR-146b-3p/RAS/RAF1/MEK/ERK pathway [108]
circ_0132266 Down proliferation (−), apoptosis ( +) / miR-337-3p/PML [30]
DLBCL circ-APC Down proliferation (−), cell cycle (−) Ann Arbor stage, CHOP-like and rituximab resistance, short OS, independent prognostic factor miR-888/APC, TET1/APC, inactivate Wnt/β-catenin pathway [33]
MCL circCDYL Up proliferation ( +) diagnosis   [34]
T-LBL circ-LAMP1 Up proliferation ( +), apoptosis (−) / miR-615-5p/DDR2 [32]
MM circ_0007841 Up proliferation ( +) clinical type, cytogenetic mutation, bone destruction, R-ISS staging, DOX resistance ABCG2 level ( +) [49]
circCDYL Up DNA synthesis ( +), apoptosis (-) ISS and DS stage, diagnosis, short OS miR-1180/YAP [35]
circ_0000190 Down proliferation (−), apoptosis ( +), tumor growth (−) ISS and DS stage, high risk, short PFS, OS miR-767-5p/MAPK pathway [37]
circ-SMARCA5 Down proliferation (−), apoptosis ( +) β2-MG level, ISS stage, short PFS and OS miR-767-5p [126]
  1. Note: (+) means promotion and (−) means suppression